A company establishes a new medical device indication for its consumer disposable products. The regulatory affairs professional is asked to give a 30-minute training session on these products to sales representatives. Which of the following subjects is the MOST important to discuss?

In which section of the ICH Common Technical Document will the overview of clinical data appear?

Which of the following situations does NOT require rapid communication to regulatory authorities?

What is the LAST stage in the development of a quality risk management process for a medical device?

According to the GHTF IVD guidance, which of the following is the CORRECT classification for a blood glucose self-testing kit?